Jan 29 (Reuters) - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based ...

As part of the deal, Repertoire Immune Medicines will develop up to three drug candidates that target the drivers of certain autoimmune diseases.

Explore the vital role of bone marrow stem cells. Learn how they drive bone remodeling, immunity, and skeletal health in this ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Autoimmune diseases are on the rise. It’s not just a hunch—autoimmune diseases are rising sharply, and the numbers are too significant to ignore. These chronic conditions, where the immune system ...

Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...

Autoimmune disorders occur when the body’s immune system cannot differentiate between cells that are its own and pathogens. Consequently, the body’s immune system attacks itself causing inflammation ...

A new study reveals a critical vulnerability in a brain receptor targeted by a rare autoimmune disease. Researchers have ...

In this post, I discuss new research on the complicated link between autoimmune diseases and eating disorders. Autoimmune diseases are chronic illnesses in which a host’s immune system fails to ...

People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or bipolar disorder, a new large-scale study says. The risk of mood disorders ...

A relatively new class of autoimmune diseases that affect the brain is making psychiatrists rethink some diagnoses.

Autoimmune diseases like lupus disproportionately affect women five to one. Researchers have finally pinpointed a unique ...